The article explores the strategic plan of Microsoft Corp. to compete in the life sciences market. The author opines that Microsoft would sell enterprise-scale solutions to biopharmaceutical companies. The company is also working with Eli Lilly and Novartis to design solutions to address the industry's needs. The statement of Michael Naimoli, director of the life sciences group of Microsoft, about the health care focus of his company is presented.